Alnylam Pharmaceuticals (ALNY) vs Roivant Sciences (ROIV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 119.9% versus a loss of 49.1%. Over five years, ROIV leads with a +488.7% price change compared with +11.6% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($31.13 billion vs $25.60 billion), about 1.2 times the size.
Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | ROIV |
|---|---|---|
| Share price | $232.68 | $35.44 |
| Market cap | $31.13B | $25.60B |
| 1-day change | +3.63% | +3.60% |
| YTD return | -41.49% | +63.32% |
| 1-year return | -49.08% | +119.85% |
| 5-year return | +11.57% | +488.70% |
| P/E ratio (TTM) | 37.83 | — |
| Forward P/E | 18.73 | — |
| EPS (TTM) | $6.15 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $8.26M |
| Revenue growth (YoY) | +65.19% | -71.57% |
| Net income (latest FY) | $313.75M | $-299.77M |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | -6235.69% |
| Net margin | 8.45% | -3629.19% |
| 52-week high | $495.55 | $42.50 |
| 52-week low | $197.81 | $15.99 |
| Distance from 52-week high | -53.05% | -16.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +59.50% | +35.67% |
| Average volume | 1.77M | 7.05M |
| Shares outstanding | 133.81M | 722.32M |
| Employees | 2,500 | 721 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed ALNY by 168.9 percentage points over the past year.
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs -71.57%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
ALNY vs ROIV FAQ
Which is bigger, Alnylam Pharmaceuticals or Roivant Sciences?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $31.13B compared with $25.60B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ALNY or ROIV?
ROIV returned +119.85% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and Roivant Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.